======= TNFAIP3 ======= == Gene Information == * **Official Symbol**: TNFAIP3 * **Official Name**: TNF alpha induced protein 3 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7128|7128]] * **UniProt**: [[https://www.uniprot.org/uniprot/P21580|P21580]] * **Interactions**: [[https://thebiogrid.org/search.php?search=TNFAIP3&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TNFAIP3|Open PubMed]] * **OMIM**: [[https://omim.org/entry/191163|Open OMIM]] == Function Summary == * **Entrez Summary**: This gene was identified as a gene whose expression is rapidly induced by the tumor necrosis factor (TNF). The protein encoded by this gene is a zinc finger protein and ubiqitin-editing enzyme, and has been shown to inhibit NF-kappa B activation as well as TNF-mediated apoptosis. The encoded protein, which has both ubiquitin ligase and deubiquitinase activities, is involved in the cytokine-mediated immune and inflammatory responses. Several transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2012]. * **UniProt Summary**: Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS- induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages. {ECO:0000269|PubMed:14748687, ECO:0000269|PubMed:15258597, ECO:0000269|PubMed:16684768, ECO:0000269|PubMed:17961127, ECO:0000269|PubMed:18164316, ECO:0000269|PubMed:18952128, ECO:0000269|PubMed:19494296, ECO:0000269|PubMed:22099304, ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:8692885, ECO:0000269|PubMed:9299557, ECO:0000269|PubMed:9882303}. |zf-A20| |OTU| |regulation of toll-like receptor 5 signaling pathway| |negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway| |negative regulation of toll-like receptor 5 signaling pathway| |negative regulation of CD40 signaling pathway| |tolerance induction to lipopolysaccharide| |regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway| |negative regulation of osteoclast proliferation| |negative regulation of toll-like receptor 3 signaling pathway| |negative regulation of nucleotide-binding oligomerization domain containing signaling pathway| |negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway| |B-1 B cell homeostasis| |protein K33-linked deubiquitination| |negative regulation of chronic inflammatory response| |protein K29-linked deubiquitination| |regulation of osteoclast proliferation| |negative regulation of toll-like receptor 2 signaling pathway| |regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway| |regulation of vascular wound healing| |regulation of CD40 signaling pathway| |protein deubiquitination involved in ubiquitin-dependent protein catabolic process| |positive regulation of hepatocyte proliferation| |regulation of germinal center formation| |regulation of chronic inflammatory response| |regulation of nucleotide-binding oligomerization domain containing signaling pathway| |negative regulation of toll-like receptor 4 signaling pathway| |regulation of toll-like receptor 3 signaling pathway| |regulation of toll-like receptor 2 signaling pathway| |protein K11-linked deubiquitination| |Lys63-specific deubiquitinase activity| |tolerance induction| |negative regulation of lipopolysaccharide-mediated signaling pathway| |negative regulation of bone resorption| |regulation of hepatocyte proliferation| |negative regulation of bone remodeling| |negative regulation of interleukin-1 beta secretion| |negative regulation of interleukin-1 secretion| |response to muramyl dipeptide| |negative regulation of tissue remodeling| |regulation of toll-like receptor 4 signaling pathway| |K63-linked polyubiquitin modification-dependent protein binding| |negative regulation of interleukin-2 production| |regulation of lipopolysaccharide-mediated signaling pathway| |B cell homeostasis| |nucleotide-binding oligomerization domain containing signaling pathway| |negative regulation of interleukin-1 beta production| |nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway| |negative regulation of cyclin-dependent protein serine/threonine kinase activity| |negative regulation of cyclin-dependent protein kinase activity| |negative regulation of endothelial cell apoptotic process| |negative regulation of B cell activation| |protein K63-linked deubiquitination| |protein K48-linked deubiquitination| |negative regulation of interleukin-1 production| |cytoplasmic pattern recognition receptor signaling pathway| |regulation of defense response to virus by host| |negative regulation of extrinsic apoptotic signaling pathway via death domain receptors| |negative regulation of toll-like receptor signaling pathway| |regulation of bone resorption| |negative regulation of epithelial cell apoptotic process| |negative regulation of interleukin-6 production| |negative regulation of I-kappaB kinase/NF-kappaB signaling| |negative regulation of type I interferon production| |negative regulation of smooth muscle cell proliferation| |regulation of interleukin-1 beta secretion| |establishment of protein localization to vacuole| |regulation of bone remodeling| |regulation of endothelial cell apoptotic process| |protein K48-linked ubiquitination| |lymphocyte homeostasis| |regulation of interleukin-2 production| |regulation of interleukin-1 secretion| |thiol-dependent ubiquitinyl hydrolase activity| |protein self-association| |regulation of extrinsic apoptotic signaling pathway via death domain receptors| |negative regulation of innate immune response| |regulation of tumor necrosis factor-mediated signaling pathway| |negative regulation of tumor necrosis factor production| |negative regulation of tumor necrosis factor superfamily cytokine production| |protein localization to vacuole| |negative regulation of cytokine secretion| |regulation of toll-like receptor signaling pathway| |leukocyte homeostasis| |cellular response to hydrogen peroxide| |negative regulation of protein ubiquitination| |regulation of defense response to virus| |regulation of tissue remodeling| |negative regulation of leukocyte proliferation| |regulation of epithelial cell apoptotic process| |ubiquitin binding| |positive regulation of animal organ morphogenesis| |regulation of interleukin-1 beta production| |negative regulation of NF-kappaB transcription factor activity| |negative regulation of protein modification by small protein conjugation or removal| |negative regulation of response to biotic stimulus| |kinase binding| |regulation of interleukin-1 production| |regulation of cyclin-dependent protein serine/threonine kinase activity| |negative regulation of extrinsic apoptotic signaling pathway| |protease binding| |regulation of cyclin-dependent protein kinase activity| |thiol-dependent ubiquitin-specific protease activity| |cellular response to antibiotic| |response to hydrogen peroxide| |regulation of type I interferon production| |pattern recognition receptor signaling pathway| |cellular response to reactive oxygen species| |negative regulation of protein secretion| |negative regulation of protein serine/threonine kinase activity| |regulation of smooth muscle cell proliferation| |negative regulation of inflammatory response| |regulation of wound healing| |negative regulation of peptide secretion| |regulation of interleukin-6 production| |positive regulation of cellular protein catabolic process| |regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains| |negative regulation of lymphocyte activation| |regulation of tumor necrosis factor production| |negative regulation of immune response| |regulation of tumor necrosis factor superfamily cytokine production| |regulation of extrinsic apoptotic signaling pathway| |regulation of adaptive immune response| |negative regulation of DNA-binding transcription factor activity| |regulation of cytokine-mediated signaling pathway| |intracellular receptor signaling pathway| |regulation of response to wounding| |negative regulation of leukocyte activation| |regulation of response to cytokine stimulus| |positive regulation of Wnt signaling pathway| |negative regulation of protein transport| |cellular response to lipopolysaccharide| |negative regulation of establishment of protein localization| |positive regulation of epithelial cell proliferation| |cellular response to molecule of bacterial origin| |response to reactive oxygen species| |negative regulation of cell activation| |homeostasis of number of cells| |regulation of protein ubiquitination| |negative regulation of secretion by cell| |regulation of cytokine secretion| |negative regulation of defense response| |regulation of B cell activation| |cellular response to toxic substance| |negative regulation of multi-organism process| |cellular response to biotic stimulus| |positive regulation of protein catabolic process| |regulation of leukocyte proliferation| |negative regulation of protein kinase activity| |negative regulation of apoptotic signaling pathway| |regulation of protein modification by small protein conjugation or removal| |negative regulation of secretion| |innate immune response-activating signal transduction| |regulation of I-kappaB kinase/NF-kappaB signaling| |cellular response to oxidative stress| |negative regulation of kinase activity| |ubiquitin-protein transferase activity| |regulation of cellular protein catabolic process| |lysosome| |regulation of animal organ morphogenesis| |activation of innate immune response| |negative regulation of cytokine production| |negative regulation of transferase activity| |protein deubiquitination| |regulation of angiogenesis| |protein modification by small protein removal| |protein polyubiquitination| |response to antibiotic| |response to lipopolysaccharide| |regulation of vasculature development| |response to molecule of bacterial origin| |regulation of epithelial cell proliferation| |regulation of inflammatory response| |positive regulation of innate immune response| |regulation of Wnt signaling pathway| |positive regulation of response to biotic stimulus| |negative regulation of response to external stimulus| |positive regulation of cellular catabolic process| |regulation of protein catabolic process| |response to oxidative stress| |regulation of apoptotic signaling pathway| |cellular response to drug| |negative regulation of protein phosphorylation| |regulation of DNA-binding transcription factor activity| |positive regulation of catabolic process| |establishment of protein localization to organelle| |negative regulation of immune system process| |negative regulation of phosphorylation| |regulation of innate immune response| |regulation of protein secretion| |regulation of immune effector process| |response to peptide| |positive regulation of defense response| |negative regulation of transport| |regulation of peptide secretion| |inflammatory response| |response to toxic substance| |negative regulation of intracellular signal transduction| |positive regulation of multi-organism process| |regulation of lymphocyte activation| |regulation of protein serine/threonine kinase activity| |protein complex oligomerization| |cellular response to lipid| |regulation of response to biotic stimulus| |ubiquitin-dependent protein catabolic process| |modification-dependent protein catabolic process| |response to inorganic substance| |modification-dependent macromolecule catabolic process| |negative regulation of phosphate metabolic process| |negative regulation of phosphorus metabolic process| |immune response-activating signal transduction| |negative regulation of cell cycle| |proteolysis involved in cellular protein catabolic process| |negative regulation of protein modification process| |immune response-regulating signaling pathway| |regulation of leukocyte activation| |positive regulation of response to external stimulus| |cellular protein catabolic process| |activation of immune response| |regulation of cell activation| |immune system development| |negative regulation of cell population proliferation| |protein catabolic process| |intracellular membrane-bounded organelle| |protein ubiquitination| |response to bacterium| |regulation of cytokine production| |regulation of protein transport| |protein localization to organelle| |regulation of peptide transport| |regulation of establishment of protein localization| |regulation of secretion by cell| |regulation of defense response| |protein modification by small protein conjugation| |regulation of multi-organism process| |negative regulation of catalytic activity| |regulation of protein kinase activity| |regulation of secretion| |regulation of cellular catabolic process| |zinc ion binding| |response to lipid| |positive regulation of immune response| |regulation of kinase activity| |negative regulation of apoptotic process| |cellular macromolecule catabolic process| |negative regulation of programmed cell death| |positive regulation of cell population proliferation| |apoptotic process| |cell migration| |regulation of transferase activity| |protein modification by small protein conjugation or removal| |regulation of catabolic process| |negative regulation of cell death| |response to organonitrogen compound| |response to drug| |regulation of protein localization| |negative regulation of cellular protein metabolic process| |macromolecule catabolic process| |programmed cell death| |cellular response to oxygen-containing compound| |organonitrogen compound catabolic process| |regulation of anatomical structure morphogenesis| |identical protein binding| |localization of cell| |cell motility| |response to nitrogen compound| |cell death| |regulation of response to external stimulus| |negative regulation of protein metabolic process| |cytoskeleton organization| |negative regulation of molecular function| |regulation of immune response| |positive regulation of immune system process| |regulation of cell cycle| |negative regulation of multicellular organismal process| |negative regulation of signal transduction| |proteolysis| |response to other organism| |response to external biotic stimulus| |locomotion| |response to biotic stimulus| |defense response| |negative regulation of cell communication| |negative regulation of signaling| |positive regulation of developmental process| |regulation of protein phosphorylation| |DNA binding| |regulation of response to stress| |regulation of apoptotic process| |movement of cell or subcellular component| |response to oxygen-containing compound| |protein-containing complex assembly| |regulation of programmed cell death| |cellular protein localization| |regulation of phosphorylation| |cellular macromolecule localization| |positive regulation of cellular protein metabolic process| |establishment of protein localization| |regulation of cell population proliferation| |negative regulation of response to stimulus| |homeostatic process| |positive regulation of signal transduction| |regulation of immune system process| |regulation of cell death| |intracellular signal transduction| |cellular response to stress| |positive regulation of protein metabolic process| |positive regulation of multicellular organismal process| |organic substance catabolic process| |regulation of phosphate metabolic process| |regulation of phosphorus metabolic process| |cellular catabolic process| |positive regulation of cell communication| |positive regulation of signaling| |regulation of intracellular signal transduction| |regulation of protein modification process| |protein-containing complex subunit organization| |regulation of transport| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp533|TNF-alpha 44ng/ml R08 exp533]]|-4.04| |[[:results:exp175|3-Bromopyruvate 7μM R04 exp175]]|-3.12| |[[:results:exp180|Dynasore 10μM R04 exp180]]|-2.8| |[[:results:exp38|Wortmannin 5μM R00 exp38]]|-2.34| |[[:results:exp359|FK-506 30μM R07 exp359]]|-2.27| |[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.11| |[[:results:exp446|4-Nitroquinoline-1-oxide 0.5μM R08 exp446]]|-1.98| |[[:results:exp240|Pyridostatin 4μM R05 exp240]]|-1.97| |[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-1.92| |[[:results:exp436|Dynasore 7μM R08 exp436]]|-1.84| |[[:results:exp343|Centrinone 0.5μM R07 exp343]]|-1.81| |[[:results:exp210|LB-100 2μM R05 exp210]]|-1.73| |[[:results:exp199|Etoposide 0.3μM R05 exp199]]|1.93| ^Gene^Correlation^ |[[:human genes:h:hars|HARS]]|0.48| Global Fraction of Cell Lines Where Essential: 0/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 7332 * **Expression level (log2 read counts)**: 7.02 {{:chemogenomics:nalm6 dist.png?nolink |}}